Аркадий Верткин - Фибрилляция предсердий

50. Morillo C., Verma A., Kuck K.H. et al. Radiofrequency Ablation vs. Antiarrhythmic Drugs as First-Line Treatment of Symptomatic Atrial Fibrillation: RAAFT 2): A randomized trial. Heart Rhythm Society 2012 Scientific Sessions; May 11, 2012; Boston, MA. Abstract LB02-1.

51. Wazni O.M., Marrouche N.F., Martin D.O., Verma A., Bhargava M., Saliba W., Bash D., Schweikert R., Brachmann J., Gunther J., Gutleben K., Pisano E., Potenza D., Fanelli R., Raviele A., Themistoclakis S., Rossillo A., Bonso A., Natale A.: Radiofrequency ablation vs antiarrhythmic drugs as firstline reatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005; 293:2634–2640.

52. Boersma L.V., Castella M., van Boven W., Berruezo A., Yilmaz A., Nadal M., Sandoval E., Calvo N., Brugada J., Kelder J., Wijffels M., Mont L. Atrial fibrillation catheter ablation vs. surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation 2012; 125:23–30.

53. Pison L., La Meir M., van Opstal J., Blaauw Y., Maessen J., Crijns H.J. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J. Am Coll Cardiol 2012; 60:54–61.

54. Connolly S.J., Ezekowitz M.D., Yusuf S., Reilly P.A., Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875–1876.

55. Connolly S.J. et al., N. Engl. J. Med 2009; 361:1139–51.

56. Hohnloser S.H., Crijns H.J., van Eickels M., Gaudin C., Page R.L., Torp-Pedersen C., Connolly S.J.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668–678.

57. K.øber L., Torp-Pedersen C., McMurray J.J., Gøtzsche O., Le´vy S., Crijns H., Amlie J., Carlsen J.; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N. Engl J. Med 2008; 358:2678–2687.

58. Duray G.Z., Schmitt J., Hohnloser S.H. Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. J Cardiovasc Pharmacol Ther 2010; 15(Suppl 4):19S–23S.

59. Stuart J. Connolly, M.D., John Eikelboom, M.B., B.S., Campbell Joyner et al. Apixaban in Patients with Atrial Fibrillation N Engl J Med 2011; 364:806-17.

60. Nieuwlaat R., Capucci A., Camm A.J., et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J2005; 26: 2422–2434.

61. Nabauer M., Gerth A., Limbourg T., et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423–434.

62. Daniel R. Ouellette, Pulmonary embolism. Treatment and management. Medscape. 2013.

63. DeMonaco N.A., Dang Q., Kapoor W.N., Ragni MV. Pulmonary embolism incidence is increasing with use of spiral computed tomography. Am J Med. Jul 2008; 121(7):611–7.

64. Prins M.H., Lensing A.W., Bauersachs R., van Bellen B., Bounameaux H., Brighton T.A., Cohen A.T., Davidson B.L., Decousus H., Raskob G.E., Berkowitz S.D., Wells PS;EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal 2013, 11:21.

65. Stefan H. Hohnloser et al. European Heart Journal 2012, Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.

66. Robert P. Giugliano, M.D., et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl J. Med 2013; 369:2093–2104 November 28, 2013.

67. Steg, P.G.; Mehta, S.R.; Jukema, J.W.; Lip, G.Y.; Gibson, C.M.; Kovar, F.; Kala, P.; Garcia-Hernandez, A.; Renfurm, R.W.; Granger, C.B.; Ruby-1, Investigators (2011). “RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome”.European heart journal 32 (20): 2541–54.

68. Adapted from Mavrakanas T, Bounameaux H. Pharmacol Ther 2011; 130:46–58.

69. Mak K.-H. BMJ Open 2012; 2:e001592.

70. Hankey G. Lancet Neurology epub ahead of print March 7, 2012.

A – Ишемический инфаркт с геморрагической трансформацией в левой височной и лобной долях.

B – постинфарктный кардиосклероз в области верхушки сердца.

C – отёк лёгких.

D – мускатная печень.

Рис. 1. Данные аутопсии больного Н., 64 года. A – Ишемический инфаркт с геморрагической трансформацией в левой височной и лобной долях. B – постинфарктный кардиосклероз в области верхушки сердца. C – отёк лёгких. D – мускатная печень.

Рис. 2. Постинфарктный кардиосклероз.

Рис. 3. Гипертрофия миокарда левого желудочка.

Рис. 4. Тромбоз вен парапростатической клетчатки.

Рис. 5. ТЭЛА мелких ветвей.

Рис. 6 A, B. Повторный ОНМК в левых подкорковых ядрах.

Рис. 6 B. Повторный ОНМК в левых подкорковых ядрах.

Рис. 7. Постинфарктный кардиосклероз с формированием хронической аневризмы ЛЖ.